Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARVE phase 2 study of cabazitaxel response by AR-V7 status in circulating tumor cells
NL-OMON43532Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Jan 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Erasmus MC. Primary endpoint: PSA response rate. Planned start Jan 2016; status: withdrawn.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON43532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43532.